Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

BACKGROUND: We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS). METHODS: Patients were randomized 2:1 to trabectedin (n = 384) or dacarbazine (n = 193) administered intravenously every 3 weeks. The primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shreyaskumar, von Mehren, Margaret, Reed, Damon R., Kaiser, Pamela, Charlson, John, Ryan, Christopher W., Rushing, Daniel, Livingston, Michael, Singh, Arun, Seth, Rahul, Forscher, Charles, D'Amato, Gina, Chawla, Sant P., McCarthy, Sharon, Wang, George, Parekh, Trilok, Knoblauch, Roland, Hensley, Martee L., Maki, Robert G., Demetri, George D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/
https://www.ncbi.nlm.nih.gov/pubmed/31173362
http://dx.doi.org/10.1002/cncr.32117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771856/
https://www.ncbi.nlm.nih.gov/pubmed/31173362
http://dx.doi.org/10.1002/cncr.32117

Ejemplares similares